Healthcare / BiotechnologyShenzhen
$15.37
-0.02 (-0.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-162.2M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.3B
P/E
1537.0x
↑EV/EBITDA
57.1x
↑ROE
-2.5%
↓Gross Margin
16.7%
↓Debt/Equity
0.76
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.4%
FCF CAGR
—
FCF margin
-13.7%
FCF / Net income
2.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.18B · net income $-55.0M · FCF $-162.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.18B | $1.18B | $1.18B | $1.61B | $1.65B |
| Net Income | $-55.0M | $-55.0M | $-272.1M | $-200.8M | $-141.5M |
| EBITDA | $168.6M | $168.6M | $-76.9M | $-31.7M | $22.2M |
| EPS | -0.10 | -0.10 | -0.51 | -0.37 | -0.26 |
| Gross Margin | 16.7% | 16.7% | 9.7% | 10.6% | 18.0% |
| Operating Margin | 0.7% | 0.7% | -7.6% | -8.2% | 2.3% |
| Net Margin | -4.6% | -4.6% | -23.1% | -12.5% | -8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.76 | 0.76 | 0.74 | 0.65 | 0.53 |
| Current Ratio | 1.22 | 1.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-162.2M | $-162.2M | $45.9M | $-307.0M | $-580.3M |
| Returns | |||||
| ROE | -2.5% | -2.5% | -12.5% | -8.1% | -5.3% |
| Valuation | |||||
| P/E | 1537.00 | 1537.00 | — | — | — |
| EV/EBITDA | 57.09 | 57.09 | — | — | 343.38 |
| P/B | 3.87 | 3.87 | 1.94 | 1.99 | 2.68 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | -26.8% | -2.3% | — |
| EPS Growth | 80.4% | 80.4% | -37.8% | -42.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+75.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.10
Residual
+75.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.